SCHEMBL23159231

SCHEMBL23159231

NNCc1cc(F)ccc1F

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 2/20 0.42
ALDH1A1 P00352 3/20 0.41
GAA P10253 1/20 0.41
MAPT P10636 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
MAPK8 P45983 1/20 0.41
PSEN1 P49768 1/20 0.40
PSEN2 P49810 1/20 0.40
APH1B Q8WW43 1/20 0.40
NCSTN Q92542 1/20 0.40
APH1A Q96BI3 1/20 0.40
PSENEN Q9NZ42 1/20 0.40
IDO1 P14902 2/20 0.39
AGXT P21549 2/20 0.39
DPP8 Q6V1X1 1/20 0.38
CA3 P07451 1/20 0.38
CA6 P23280 1/20 0.38
CA5A P35218 1/20 0.38
CA9 Q16790 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL15065772 0.98 ALDH1A1 (0.44) DPP4ALDH1A1GAAMAPTMEN1
SCHEMBL1757600 0.83 IDO1 (0.53) ALDH1A1GAAMAPK8IDO1AGXT
SCHEMBL8223792 0.81 MEN1 (0.42) ALDH1A1MAPTMEN1KMT2AIDO1
Hydrochloric Acid SCHEMBL21332846 0.81 IDO1 (0.55) ALDH1A1GAAMAPTMAPK8IDO1
Hydrochloric Acid SCHEMBL15065821 0.81 IDO1 (0.55) ALDH1A1GAAMAPTMAPK8IDO1
SCHEMBL29289498 0.79 DPP4 (0.40) DPP4ALDH1A1MAPK8PSEN1PSEN2
SCHEMBL28141955 0.78 MEN1 (0.44) DPP4ALDH1A1MEN1KMT2AMAPK8
SCHEMBL3127209 0.78 SLC6A4 (0.54) HTR2ASLC6A4KCNH2
SCHEMBL24018757 0.76 IDO1 (0.57) ALDH1A1MAPTMEN1KMT2AIDO1
SCHEMBL18656738 0.76 MAPK8 (0.44) ALDH1A1MAPTKMT2AMAPK8RIPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11718612-B2 Inhibitors of receptor interacting protein kinase I for the treatment of disease BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2023-08-08 US disclosed
US-11718612-B2 Inhibitors of receptor interacting protein kinase I for the treatment of disease BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2023-08-08 US disclosed
WO-2022258052-A1 HETEROCYCLIC LACTAM COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF 劲方医药科技(上海)有限公司 2022-12-15 WO disclosed
US-20210094951-A1 INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2021-04-01 US disclosed
CN-104066731-A 2-benzyl, 3- (pyrimidin-2-yl) substituted pyrazoles useful as SGC stimulators IRONWOOD PHARMACEUTICALS INC 2014-09-24 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11718612-B2 Inhibitors of receptor interacting protein kinase I for the treatment of disease RIPK1, RIPK2, RIPK4 DPP4 3242/4885ALDH1A1 4554/4885GAA 2476/4885
US-20210094951-A1 INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE RIPK1, RIPK2, RIPK4 DPP4 3242/4885ALDH1A1 4554/4885GAA 2476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.